Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. The licence refers to an intellectual property portfolio owned by the MDC covering novel chimeric antigen receptor (CAR) constructs that specifically bind B-cell maturation antigen (BCMA). Under the agreement, Fate Therapeutics obtains the exclusive right to use the portfolio for all cell products, including CAR NK-cell and T-cell products, derived from induced pluripotent stem cells (iPSCs). The licence follows an option agreement that was also supported by Ascenion and signed by the partners at the end of 2018.
Further information
See Fate’s press release relating to the option agreement